Domestic Market Overview - The market showed a mixed performance on February 26, with the Shanghai Composite Index closing at 4146.63 points, down 0.01%, while the Shenzhen Component Index rose 0.19% to 14503.79 points. The STAR 50 Index increased by 0.85%, and the ChiNext Index fell by 0.29%. The total trading volume of the A-share market reached 25,566 billion yuan, continuing to rise from the previous day [1][5][10] - Among the 30 sectors tracked by CITIC, 11 sectors saw gains, with telecommunications, electronics, and defense industries leading the increases. Conversely, real estate, non-bank financials, and consumer services experienced significant declines. Notably, indices related to circuit boards, optical circuit switches, and copper-clad laminates performed actively [1][5][10] Overseas Market Overview - On February 26, the three major U.S. stock indices closed mixed, with the Dow Jones Industrial Average up 0.03%, the S&P 500 down 0.54%, and the Nasdaq down 1.18%. The Wande American Technology Seven Giants Index fell by 1.87%, with Nvidia dropping over 5% and Tesla declining by more than 2%. The Nasdaq China Golden Dragon Index fell by 1.78%, with SMIC down over 16% and BeiGene down more than 8% [2][5] News Highlights - The Ministry of Commerce responded to the upcoming sixth round of China-U.S. economic and trade consultations, emphasizing the importance of maintaining communication and cooperation between the two countries [3][12] - The People's Bank of China issued a notice regarding the cross-border interbank financing business for banking financial institutions, supporting domestic banks in conducting such business in a compliant and risk-controlled manner [3][12] - The offshore RMB against the U.S. dollar broke through the 6.83 mark, rising approximately 260 basis points during the day [3][13] - Global debt has surged to a record 348 trillion U.S. dollars, marking the fastest growth since the onset of the COVID-19 pandemic [3][17]

Group 1 - The core viewpoint of the report is that the company maintains a "Buy" rating for BeiGene (06160) and has adjusted its profit forecasts for 2026-2028, expecting net profits of 2.47 billion, 4.15 billion, and 5.56 billion RMB, with year-over-year growth rates of +73%, +68%, and +34% respectively [1] - The company reported total revenue of 38.21 billion RMB for 2025, a year-over-year increase of 40.4%, with product revenue at 37.77 billion RMB, showing a growth of 39.9% [1] - In Q4 alone, the company achieved revenue of 10.61 billion RMB, reflecting a year-over-year growth of 31.3%, and a net profit of 280 million RMB [1] Group 2 - The main driver of revenue growth is the self-developed product, Zebrutinib (百悦泽), which generated global sales of 28.1 billion USD, marking a year-over-year increase of 48.8%, with the largest market being the US at 20.2 billion RMB, a growth of 46% [2] - The sales of another product, Tislelizumab (百泽安), reached 5.3 billion RMB, with a year-over-year growth of 19%, primarily due to new approvals and increased hospital admissions in China [2] Group 3 - The company has provided guidance for 2026, expecting revenue to be between 43.6 billion and 45 billion RMB, representing a year-over-year growth of 14% to 18%, with a gross margin projected to remain high at 80% [3] - GAAP operating profit is expected to be between 4.6 billion and 5.3 billion RMB, while non-GAAP operating profit is projected to be between 9.8 billion and 10.5 billion RMB [3]

Group 1 - The core viewpoint of the report is that Guotai Junan Securities maintains a "Buy" rating for BeiGene (06160), adjusting profit forecasts based on the company's latest guidance, with expected net profits for 2026-2028 at 2.47 billion, 4.15 billion, and 5.56 billion RMB, representing year-over-year growth of 73%, 68%, and 34% respectively [1] - The company reported total revenue of 38.21 billion RMB for 2025, a year-over-year increase of 40.4%, with product revenue at 37.77 billion RMB, up 39.9% [1] - In Q4 alone, the company achieved revenue of 10.61 billion RMB, a year-over-year increase of 31.3%, and recorded a net profit of 280 million RMB [1] Group 2 - The main growth driver for the company is the self-developed product, Zebrutinib (百悦泽), which generated global sales of 28.1 billion USD, reflecting a year-over-year increase of 48.8%, with the largest market being the U.S. at 20.2 billion RMB, up 46% [2] - The sales of another product, Tislelizumab (百泽安), reached 5.3 billion RMB, a year-over-year increase of 19%, primarily due to new approvals and increased hospital admissions in China [2] Group 3 - The company has provided guidance for 2026, expecting revenue to be between 43.6 billion and 45 billion RMB, representing a year-over-year growth of 14% to 18%, with a gross margin expected to remain high at 80% [3] - GAAP operating profit is projected to be between 4.6 billion and 5.3 billion RMB, while non-GAAP operating profit is expected to be between 9.8 billion and 10.5 billion RMB [3]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][6]. Core Insights - The company achieved a revenue growth of 40% in 2025, marking its first year of profitability, with commercial success becoming evident [6][8]. - The primary revenue driver is the self-developed product, Zebutinib, which generated global sales of $28.1 billion, reflecting a year-over-year increase of 48.8% [8]. - The company provided guidance for 2026, expecting revenue between RMB 43.6 billion and RMB 45 billion, representing a year-over-year growth of 14% to 18% [8]. - Profit forecasts for 2026 to 2028 indicate net profits of RMB 2.47 billion, RMB 4.15 billion, and RMB 5.56 billion, with respective year-over-year growth rates of 73%, 68%, and 34% [8]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology sector, with a current H-share price of HKD 194.40 and a target price of HKD 229 [2][5]. Financial Performance - In 2025, the company reported total revenue of RMB 38.21 billion, a 40.4% increase year-over-year, with product revenue contributing RMB 37.77 billion [8]. - The net profit for 2025 was RMB 1.42 billion, a significant recovery from a net loss of RMB 4.98 billion in the previous year [8]. Earnings Forecast - The earnings per share (EPS) for 2026 is projected at RMB 2.4, with a price-to-earnings (P/E) ratio of 70 times [7][8]. - The company anticipates maintaining a high gross margin of around 80% in 2026 [8]. Market Position - The major shareholder is Amgen, holding 15.98% of the company [2]. - The stock has shown a year-over-year increase of 35.47% [2].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][6]. Core Insights - The company achieved a revenue growth of 40% in 2025, marking its first year of profitability, with commercial success becoming evident [6][8]. - The primary revenue driver is the self-developed product, Zebutini (BTK inhibitor), which generated global sales of $28.1 billion, reflecting a year-over-year increase of 48.8% [8]. - The company provided guidance for 2026, expecting revenue between RMB 43.6 billion and RMB 45 billion, representing a year-over-year growth of 14% to 18% [8]. - Profit forecasts for 2026 to 2028 are adjusted to RMB 2.47 billion, RMB 4.15 billion, and RMB 5.56 billion, with respective year-over-year growth rates of 73%, 68%, and 34% [8]. Financial Summary - The company reported total revenue of RMB 38.21 billion for 2025, with product revenue contributing RMB 37.77 billion, a year-over-year increase of 39.9% [8]. - The net profit for 2025 was RMB 1.42 billion, a significant recovery from a net loss of RMB 4.98 billion in the previous year [8]. - The earnings per share (EPS) for 2025 is projected at RMB 1.40, with a forecasted increase to RMB 2.43 in 2026 [7][8]. - The company’s market capitalization is approximately RMB 171.82 billion, with a price-to-earnings (P/E) ratio of 121.42 for H shares in 2025 [2][7]. Market Performance - The stock price as of February 26, 2026, was HKD 194.40, with a target price set at HKD 229, indicating a potential upside [2][5]. - The stock has experienced a year-to-date increase of 35.47% [2].

Core Viewpoint - Haitong International maintains an "outperform" rating for BeiGene (06160), with revenue forecasts for FY26 and FY27 at $6.4 billion and $7.1 billion respectively, and slightly adjusts net profit forecasts to $610 million and $1.04 billion for the same periods [1] Group 1: Financial Performance - In 2025, BeiGene achieved revenue of $5.34 billion, a year-on-year increase of 40%, with product revenue of $5.28 billion, slightly exceeding previous management guidance [1] - The net profit attributable to shareholders for 2025 was $290 million, marking a turnaround in annual recurring business [1] - Management anticipates revenue of $6.2 billion to $6.4 billion for 2026, with GAAP operating profit projected at $700 million to $800 million [1] Group 2: Product Performance - Zepzelca generated revenue of $3.93 billion for the year, a 49% increase year-on-year, with U.S. sales at $2.8 billion (up 45%), European sales at $600 million (up 66%), and Chinese sales at $340 million (up 33%) [2] - The quarterly revenue for Zepzelca in Q4 2025 was $1.15 billion, reflecting a 10% increase quarter-on-quarter and a 38% increase year-on-year [2] - Tislelizumab achieved annual revenue of $740 million, a 19% increase year-on-year, with Q4 2025 revenue of $180 million, up 18% year-on-year [2] - Collaborative product sales in China totaled $620 million for the year, a 20% increase, driven by growth in Duzallo and Belantamab Mafodotin [2] Group 3: Upcoming Catalysts - Key catalysts for 1H26 include the approval of Sotigalimab for R/RMCL in the U.S., interim analysis of Zepzelca in 1L-MCL Phase III, initiation of CDK4 in 1L-HR+ HER2- BC Phase III, and data readout for BTKCDAC in moderate to severe chronic spontaneous urticaria Phase Ib [3] - In 2H26, key catalysts include submission of BTKCDAC for accelerated approval based on Phase II clinical data for R/R-CLL, initiation of Sotigalimab in a triplet regimen for 2L+ multiple myeloma Phase III, and expected initiation of BGB-B2033 (GPC3x41BB) for gastrointestinal cancer in a potential registrational Phase II study [3]

Group 1 - The core viewpoint of Haitong International maintains an "outperform" rating for BeiGene (06160), with revenue forecasts for FY26 and FY27 at $6.4 billion and $7.1 billion respectively, and a slight adjustment of net profit forecasts to $610 million and $1.04 billion [1] - The company achieved revenue of $5.34 billion in 2025, a year-on-year increase of 40%, with product revenue of $5.28 billion, slightly exceeding previous management guidance [1] - Management anticipates revenue of $6.2 billion to $6.4 billion in 2026, with GAAP operating profit projected at $700 million to $800 million [1] Group 2 - The revenue for Zebutini reached $3.93 billion in 2025, reflecting a 49% year-on-year growth, with U.S. sales at $2.8 billion (up 45%), European sales at $600 million (up 66%), and Chinese sales at $340 million (up 33%) [2] - The revenue for Tislelizumab was $740 million in 2025, showing a 19% year-on-year increase, with Q4 2025 revenue at $180 million (up 18%) [2] - Revenue from collaborative products in China was $620 million, a 20% increase, driven by growth in Duzallo and Belantamab Mafodotin [2] Group 3 - Key catalysts for 1H26 include the approval of Sotigalimab for R/RMCL in the U.S., interim analysis of Zebutini in the Phase III trial for 1L MCL, and the expected initiation of Phase III clinical trials for CDK4 in HR+ HER2- BC [3] - In 2H26, key catalysts include the submission of an accelerated approval application for BTKCDAC based on Phase II clinical data for R/R CLL, initiation of a Phase III trial for Sotigalimab in combination therapy for 2L+ multiple myeloma, and expected initiation of a potential registration Phase II study for BGB-B2033 in gastrointestinal cancer [3]

Core Insights - BeiGene reported a total revenue of 38.205 billion RMB for the fiscal year 2025, marking a 40.4% year-on-year increase, driven by product revenue growth and improved operational efficiency [1] - The net profit attributable to the parent company reached 1.422 billion RMB, indicating a significant turnaround from previous losses [1] - The company's flagship product, Brukinsa (Zebutinib), achieved global sales of 28.067 billion RMB, a 48.8% increase, solidifying its position as a global leader in the BTK inhibitor market [1][2] Revenue Breakdown - Product revenue for BeiGene reached 37.770 billion RMB, up 39.9%, primarily due to the sales growth of Brukinsa, Amgen-licensed products, and Tislelizumab [1][2] - In the U.S. market, Brukinsa's annual sales were 20.206 billion RMB, a 45.5% increase; in Europe, sales reached 4.265 billion RMB, up 66.4%; and in China, sales were 2.472 billion RMB, a 33.1% increase [1] Product Approvals and Pipeline - Brukinsa is the most widely approved BTK inhibitor globally, with approvals in over 75 markets [2] - The company plans to conduct a mid-term analysis of the MANGROVE trial in the first half of 2026, comparing Brukinsa combined with Rituximab against Bendamustine plus Rituximab for adult patients with mantle cell lymphoma [2] - Tislelizumab's global sales reached 5.297 billion RMB, an 18.6% increase, with ongoing efforts to submit new indications for regulatory approval in the U.S. and China [2] Market Position and Future Outlook - Analysts noted that BeiGene's transition from a "cash-burning machine" to a "cash-generating machine" reflects a significant shift in the global strategy for Chinese innovative drugs [3] - The company is expected to generate revenue between 43.6 billion and 45 billion RMB in 2026, with a gross margin projected to remain high at around 80% [4] - Concerns remain regarding the pipeline for new products following Brukinsa and Tislelizumab, with several late-stage candidates nearing commercialization [4][5] Strategic Initiatives - BeiGene is exploring the introduction of BTK inhibitors and IRAK4 degraders into autoimmune diseases, which could expand its market reach beyond oncology [5] - The company has received priority review status from the FDA for its BCL2 inhibitor, which is aimed at treating adult patients with relapsed/refractory mantle cell lymphoma [4][5] - The market is keenly awaiting the potential of new innovative candidates to emerge from BeiGene's pipeline, which could further enhance its valuation in the long term [5]

Core Viewpoint - BeiGene has reported a significant increase in revenue and net profit for the fiscal year 2025, indicating a successful transition from a loss-making entity to a profitable one, driven by strong product sales and effective cost management [1][3]. Financial Performance - Total revenue for 2025 reached RMB 38.205 billion, a year-on-year increase of 40.4% [1]. - Net profit attributable to the parent company was RMB 1.422 billion [1]. - Product revenue amounted to RMB 37.770 billion, reflecting a growth of 39.9% [1]. Product Performance - The sales of the leading product, Brukinsa® (Zebutinib), reached RMB 28.067 billion, marking a 48.8% increase [1]. - In the U.S., Brukinsa® sales were RMB 20.206 billion, up 45.5% [1]. - In Europe, sales were RMB 4.265 billion, a growth of 66.4% [1]. - In China, sales reached RMB 2.472 billion, increasing by 33.1% [1]. Market Expansion and Clinical Trials - Brukinsa® is now approved in over 75 markets globally, establishing itself as the most widely approved BTK inhibitor [2]. - Upcoming clinical trials include a mid-term analysis of the MANGROVE trial for Brukinsa® in combination with Rituximab for adult patients with mantle cell lymphoma [2]. - The sales of another key product, Tislelizumab (百泽安®), reached RMB 5.297 billion, an 18.6% increase [2]. Future Projections - Revenue for 2026 is projected to be between RMB 43.6 billion and RMB 45 billion, with a gross margin expected to remain high at around 80% [4]. - Research and development expenses are anticipated to be between RMB 33.3 billion and RMB 34.8 billion [4]. Pipeline and Innovation - The company is advancing several late-stage products in the hematologic oncology field, including the BCL2 inhibitor, which has received approval for its first global marketing application in China [4]. - The introduction of BTK inhibitors and IRAK4 degraders into autoimmune diseases represents a strategic expansion into non-oncology markets [5]. Market Position and Valuation - Despite achieving profitability, the company's market valuation remains high, with a significant price-to-earnings ratio, indicating that the market views it as a growth stock rather than a value stock [5].

Summary of Conference Call Records Company and Industry Involved - The conference call pertains to **百济神州 (BeiGene)**, a biopharmaceutical company focused on developing innovative medicines for cancer treatment, particularly in the field of hematology and oncology. Core Points and Arguments - **Performance of Zebutini**: The management team remains optimistic about the performance of Zebutini, despite the limited impact from the non-covalent BTK inhibitor Pirto. The efficacy comparison shows Zebutini with a median follow-up of 42.5 months and a PFS HR of 0.69, while Pirto has a median follow-up of 18.2 months with a PFS HR of 0.845 [1][2]. - **CLL Market Dynamics**: The company believes that current data indicates Pirto is unlikely to disrupt the CLL (Chronic Lymphocytic Leukemia) treatment landscape. The combination of Soron and Zanu presents a potential opportunity to expand into the CLL market, where ven-based FD and other therapies hold approximately 50% market share [2]. - **Upcoming Clinical Trials**: Three Phase III trials for BCL-2 inhibitors are set to commence, including one against AV in 2026. The company is also optimistic about the potential of its solid tumor POC assets to enter late-stage development, driven by external data catalysts [2]. - **CDK4 Inhibitors**: The CDK4 inhibitor shows better selectivity compared to Atirmociclib, with high ORR (Overall Response Rate) and reduced blood toxicity. The company plans to present CDK4i data at an academic conference [2]. - **B7-H4 ADC Development**: The B7-H4 ADC has demonstrated good efficacy and safety in gynecological tumors, leading to an accelerated internal development process [2]. - **PRMT5 Inhibitor**: This compound shows good brain permeability and selectivity, with promising clinical efficacy and safety [2]. - **FDA Fast Track Designation**: The GPC3 x 4-1BB bispecific antibody has received FDA fast track designation, indicating its potential significance in treatment [2]. - **Upcoming Approvals and Submissions**: The company anticipates several key milestones, including the approval of SoronRRMCL in the U.S. in the first half of 2026, and plans to submit an accelerated review application for BTK CDAC based on Phase II data in the same timeframe [2]. Other Important but Possibly Overlooked Content - The management emphasizes the strategic importance of entering new markets and expanding treatment options for CLL patients, which could significantly enhance the company's market position [2]. - The focus on clinical data and upcoming trials indicates a robust pipeline that could lead to future growth and revenue generation for the company [2].